AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Applied DNA Sciences Inc. (APDN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.16

-0.00 (-2.26%)

At close: Feb 20, 2025, 3:59 PM

0.16

-0.80%

After-hours: Feb 20, 2025, 06:18 PM EST

undefined% (undefined)

Bid	0.16
Market Cap	9.00M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.65
PE Ratio (ttm)	-0.25
Forward PE	n/a
Analyst	Buy

Ask	0.17
Volume	1,522,617
Avg. Volume (20D)	5,507,964
Open	0.16
Previous Close	0.16
Day's Range	0.16 - 0.16
52-Week Range	0.12 - 14.40
Beta	undefined

About APDN

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection ...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Jul 15, 2003

Employees 46

Stock Exchange NASDAQ

Ticker Symbol APDN

Website https://www.adnas.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for APDN stock is "Buy." The 12-month stock price forecast is $1.5, which is an increase of 819.68% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago

+24.46%

Applied DNA Sciences shares are trading lower afte... Unlock content with Pro Subscription

3 months ago

-40.56%

Applied DNA shares are trading lower after the company announced the pricing of a registered direct offering of 20,312,500 shares at $0.32 per share. The company also announced a concurrent private placement.

News

6 days ago · seekingalpha.com

Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript

Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantz...

1 week ago · zacks.com

Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates

Applied DNA Sciences (APDN) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.80 per share a year ago.

1 week ago · accessnewswire.com

Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified fo...

1 week ago · accessnewswire.com

Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polym...

1 week ago · accessnewswire.com

Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14

STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to it...

2 months ago · zacks.com

Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates

Applied DNA Sciences (APDN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $5.20 per share a year ago.